Expanded Access to Glecaprevir/ Pibrentasvir

Official Title: 
Expanded Access to Glecaprevir/ Pibrentasvir
Brief Summary: 
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to glecaprevir/ pibrentasvir prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Approved for marketing
EA Type
Individual Patients
Hepatitis C Virus Infection

Drug: glecaprevir
Glecaprevir will be administered orally.
Other Name: ABT-493

Drug: pibrentasvir
Pibrentasvir will be administered orally.
Other Name: ABT-530

Eligibility Gender: 
Eligibility Age: 
Minimum: 18 Years

AbbVie Inc.
Study Director

EA Number: 
Special Access Scheme, Expanded Access, Pre-approval Access, Compassionate Use, Special Access Program, Named Patient Basis
MeSH Terms: 
Hepatitis C, Virus Diseases
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about